PL372413A1 - Fosforanowe proleki fluorooksindoli - Google Patents

Fosforanowe proleki fluorooksindoli

Info

Publication number: PL372413A1
Authority: PL; Poland
Prior art keywords: fluorooxindoles; phosphate prodrugs; prodrugs; phosphate
Prior art date: 2002-03-20

Application number

PL03372413A

Other languages

English (en)

Inventor

Kevin W. Gillman

Piyasena Hewawasam

William D. Schmitz

Omar D. Lopez

John E. Starrett

David P. Provencal

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-20

Filing date

2003-03-20

Publication date

2005-07-25

2003-03-20 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2005-07-25 Publication of PL372413A1 publication Critical patent/PL372413A1/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL03372413A 2002-03-20 2003-03-20 Fosforanowe proleki fluorooksindoli PL372413A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36601002P	2002-03-20	2002-03-20

Publications (1)

Publication Number	Publication Date
PL372413A1 true PL372413A1 (pl)	2005-07-25

Family

ID=28454740

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03372413A PL372413A1 (pl)	2002-03-20	2003-03-20	Fosforanowe proleki fluorooksindoli

Country Status (21)

Country	Link
US (1)	US6930100B2 (pl)
EP (1)	EP1485085A4 (pl)
JP (1)	JP4359150B2 (pl)
KR (1)	KR100951499B1 (pl)
CN (1)	CN100384820C (pl)
BR (1)	BR0308737A (pl)
CA (1)	CA2479256A1 (pl)
CO (1)	CO5611143A2 (pl)
GE (1)	GEP20074230B (pl)
HR (1)	HRP20040853A2 (pl)
IL (2)	IL164022A0 (pl)
IS (1)	IS7456A (pl)
MX (1)	MXPA04008999A (pl)
NO (1)	NO20044442L (pl)
NZ (1)	NZ535365A (pl)
PL (1)	PL372413A1 (pl)
RS (1)	RS81904A (pl)
RU (1)	RU2312857C2 (pl)
UA (1)	UA77296C2 (pl)
WO (1)	WO2003080047A1 (pl)
ZA (1)	ZA200407337B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
ES2445208T3 (es)	2002-07-29	2014-02-28	Rigel Pharmaceuticals, Inc.	Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
US6916937B2 (en) *	2003-02-03	2005-07-12	Bristol-Myers Squibb Company	Carbohydrate prodrugs of fluorooxindoles
BRPI0413018B8 (pt)	2003-07-30	2021-05-25	Rigel Pharmaceuticals Inc	composto, e, uso de um composto
US7169803B2 (en) *	2004-03-15	2007-01-30	Bristol-Myers Squibb Company	N-substituted prodrugs of fluorooxindoles
US7253167B2 (en)	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
DE602006010979D1 (de)	2005-01-19	2010-01-21	Rigel Pharmaceuticals Inc	Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US8227455B2 (en)	2005-04-18	2012-07-24	Rigel Pharmaceuticals, Inc.	Methods of treating cell proliferative disorders
JP4981673B2 (ja) *	2005-09-13	2012-07-25	エーザイ・アール・アンド・ディー・マネジメント株式会社	安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物およびその製造方法
TWI385169B (zh)	2005-10-31	2013-02-11	Eisai R&D Man Co Ltd	經雜環取代之吡啶衍生物及含有彼之抗真菌劑
TW200841879A (en) *	2007-04-27	2008-11-01	Eisai R&D Man Co Ltd	Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) *	2007-12-27	2013-08-20	Eisai R&D Management Co., Ltd.	Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
AU2009212514A1 (en) *	2008-02-05	2009-08-13	Merck Sharp & Dohme Corp.	Prodrugs of CGRP receptor antagonist
US8188119B2 (en) *	2008-10-24	2012-05-29	Eisai R&D Management Co., Ltd	Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
CA2937222C (en) *	2009-06-25	2019-06-04	Alkermes Pharma Ireland Limited	Prodrugs of nh-acidic compounds
LT2445502T (lt)	2009-06-25	2017-09-25	Alkermes Pharma Ireland Limited	Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
AU2011270701B2 (en)	2010-06-24	2015-05-14	Alkermes Pharma Ireland Limited	Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
KR101974793B1 (ko)	2015-07-06	2019-05-02	길리애드 사이언시즈, 인코포레이티드	Cot 조정제 및 그의 사용 방법
KR20200121800A (ko)	2018-01-05	2020-10-26	싸이브렉사 1, 인크.	산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
EP3761983A1 (en)	2018-03-05	2021-01-13	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
ES2975753T3 (es) *	2018-03-05	2024-07-12	Teon Therapeutics Inc	Antagonistas del receptor de adenosina y usos de los mismos
TWI770527B (zh)	2019-06-14	2022-07-11	美商基利科學股份有限公司	Cot 調節劑及其使用方法
TW202116356A (zh)	2019-07-10	2021-05-01	美商斯布雷克薩三號公司	作為治療劑之微管靶向藥劑之肽結合物
CN114341162B (zh)	2019-07-10	2025-10-17	赛博克萨2公司	作为治疗剂的细胞毒素的肽缀合物
AU2021249010B2 (en)	2020-03-30	2024-09-26	Gilead Sciences, Inc.	Solid forms of (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
JP7446475B2 (ja)	2020-04-02	2024-03-08	ギリアードサイエンシーズ，インコーポレイテッド	Ｃｏｔ阻害剤化合物を調製するためのプロセス
EP3912625A1 (en)	2020-05-20	2021-11-24	Kaerus Bioscience Limited	Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
WO2025233532A1 (en)	2024-05-10	2025-11-13	Les Laboratoires Servier	Maxi-k potassium channel openers and therapeutic applications thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU749063A1 (ru) *	1979-01-29	1996-09-10	Военно-медицинская академия им.С.М.Кирова	3-(4-карбэтокси)-фенилимино-2-оксоиндолин, повышающий устойчивость организма к повторной черепно-мозговой травме
US5234947A (en)	1991-11-07	1993-08-10	New York University	Potassium channel activating compounds and methods of use thereof
US5187173A (en) *	1991-12-27	1993-02-16	Sterling Winthrop Inc.	2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5565483A (en) *	1995-06-07	1996-10-15	Bristol-Myers Squibb Company	3-substituted oxindole derivatives as potassium channel modulators
KR20010033811A (ko)	1997-12-31	2001-04-25	토마스 안 빅토리아	2차 및 3차 아민을 함유하는 약제의 물에 용해가능한프로드럭 및 그것의 제조방법
PT1056754E (pt) *	1998-01-29	2004-03-31	Bristol Myers Squibb Co	Derivados fosfatados de 1,3,4-oxadiazolona de diarilo

2003
- 2003-03-20 HR HRP20040853 patent/HRP20040853A2/xx not_active Application Discontinuation
- 2003-03-20 NZ NZ535365A patent/NZ535365A/en not_active IP Right Cessation
- 2003-03-20 UA UA20041109513A patent/UA77296C2/uk unknown
- 2003-03-20 CA CA002479256A patent/CA2479256A1/en not_active Abandoned
- 2003-03-20 BR BR0308737-9A patent/BR0308737A/pt not_active IP Right Cessation
- 2003-03-20 IL IL16402203A patent/IL164022A0/xx active IP Right Grant
- 2003-03-20 RU RU2004131201/04A patent/RU2312857C2/ru not_active IP Right Cessation
- 2003-03-20 GE GEAP8458A patent/GEP20074230B/en unknown
- 2003-03-20 RS YUP-819/04A patent/RS81904A/sr unknown
- 2003-03-20 MX MXPA04008999A patent/MXPA04008999A/es active IP Right Grant
- 2003-03-20 JP JP2003577875A patent/JP4359150B2/ja not_active Expired - Fee Related
- 2003-03-20 EP EP03711659A patent/EP1485085A4/en not_active Withdrawn
- 2003-03-20 US US10/393,031 patent/US6930100B2/en not_active Expired - Lifetime
- 2003-03-20 KR KR1020047014626A patent/KR100951499B1/ko not_active Expired - Fee Related
- 2003-03-20 PL PL03372413A patent/PL372413A1/pl not_active Application Discontinuation
- 2003-03-20 WO PCT/US2003/008613 patent/WO2003080047A1/en not_active Ceased
- 2003-03-20 CN CNB038109778A patent/CN100384820C/zh not_active Expired - Fee Related
2004
- 2004-09-12 IL IL164022A patent/IL164022A/en not_active IP Right Cessation
- 2004-09-13 ZA ZA200407337A patent/ZA200407337B/en unknown
- 2004-09-17 IS IS7456A patent/IS7456A/is unknown
- 2004-09-20 CO CO04093294A patent/CO5611143A2/es not_active Application Discontinuation
- 2004-10-19 NO NO20044442A patent/NO20044442L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1485085A4 (en)	2007-03-14
RU2004131201A (ru)	2005-05-10
BR0308737A (pt)	2005-01-11
NO20044442L (no)	2004-10-19
US6930100B2 (en)	2005-08-16
IL164022A (en)	2008-04-13
HRP20040853A2 (en)	2004-12-31
CO5611143A2 (es)	2006-02-28
IS7456A (is)	2004-09-17
UA77296C2 (en)	2006-11-15
CN1652769A (zh)	2005-08-10
AU2003215017A1 (en)	2003-10-08
JP2005526097A (ja)	2005-09-02
JP4359150B2 (ja)	2009-11-04
GEP20074230B (en)	2007-11-12
CA2479256A1 (en)	2003-10-02
KR100951499B1 (ko)	2010-04-07
RS81904A (sr)	2007-02-05
MXPA04008999A (es)	2004-12-07
CN100384820C (zh)	2008-04-30
EP1485085A1 (en)	2004-12-15
US20030195169A1 (en)	2003-10-16
RU2312857C2 (ru)	2007-12-20
NZ535365A (en)	2006-07-28
KR20040106293A (ko)	2004-12-17
IL164022A0 (en)	2005-12-18
ZA200407337B (en)	2006-02-22
WO2003080047A1 (en)	2003-10-02

Legal Events

Date	Code	Title	Description
2012-09-28	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
HRP20040853A2 (en)	2004-12-31	Phosphate prodrugs of fluorooxindoles
PL371526A1 (pl)	2005-06-27	Związki zawierające fosfor i ich zastosowanie
IL212689A0 (en)	2011-07-31	Prodrugs of 9 - aminomethyl tetracycline compounds
EG23458A (en)	2005-10-02	Set of elements for assemlying structures
EP1549316A4 (en)	2008-04-09	HAMMER OF TFGbeta
AU2003211052A1 (en)	2003-09-04	Phospholipids as caspase inhibitor prodrugs
AU2003236991A8 (en)	2003-12-19	Representations of processes
EP1511488A4 (en)	2008-11-19	HUMAN INHIBITORS OF ADAM 10
AU2003287605A8 (en)	2004-06-03	Polymeric prodrugs of vancomycin
IL165475A0 (en)	2006-01-15	Nitrooxyderivatives of eyclooxygenase-2 inhibitors
AU148927S (en)	2002-08-14	Section of an orthotic insert
AU2003215796A8 (en)	2003-10-20	Audio distribution
AU148928S (en)	2002-08-14	Section of an orthotic insert
AU2003288237A1 (en)	2004-07-09	Artificial esterases
AU2003245627A8 (en)	2004-01-06	Kinases and phosphatases
AU2003287427A8 (en)	2004-06-07	Kinases and phosphatases
AU2003304244A8 (en)	2005-01-13	Epoxy-stabilized polyphosphate compositions
HK1067074A (en)	2005-04-01	Phosphate prodrugs of fluorooxindoles
AU2003231531A8 (en)	2003-11-10	Kinases and phosphatases
GB0223783D0 (en)	2002-11-20	Didgeridoo manufacture
AU2003240435A8 (en)	2004-01-06	Pna prodrugs
GB2393207B (en)	2006-04-12	Means of assembly
GB2388512B (en)	2005-08-17	Management of forests
IL152163A0 (en)	2003-05-29	Watersoluble prodrugs of propofol
PL356853A1 (pl)	2004-05-17	Zastosowanie bakteriofagów